Advertisement

Latest News

Upadacitinib Safety in Real-World Crohn’s Disease Care, With Raja Atreya, MD

50 minutes ago

Raja Atreya, MD, reviews adverse events and treatment discontinuation through week 26 in the real-world UPlift study.

PanAdipo AI Tool Proves Efficacy of AI-Enabled Cardiography for Characterizing EAT

1 hour ago

Evangelos Oikonomou, MD, discusses the newly-developed deep-learning model and how it effectively characterizes epicardial adipose tissue and cardiovascular risk.

Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD

1 hour ago

UPlift interim data show 70.2% achieved clinical response within 12 weeks, with a median time to first response of 13 days.

Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial Integrity

4 hours ago

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies

20 hours ago

Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.

Advertisement
Advertisement